KRAS Inhibitors Targeting P-Loop for Mutant Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KRAS-G12C inhibitors are insufficient for effectively targeting other prevalent KRAS mutations such as KRAS-G12D and KRAS-G12V, as these mutants lack reactive cysteines in their active site, necessitating different approaches to inhibit their activity in cancers like pancreatic ductal adenocarcinoma, colorectal cancer, and lung adenocarcinoma.
Innovation Solution
Development of small molecule inhibitors, specifically compounds of Formula (I), which modulate the activity of KRAS-G12C, KRAS-G12D, and KRAS-G12V proteins by targeting alternative sites, thereby affecting the signaling pathways associated with oncological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If covalent inhibitors targeting the cysteine residue are used to inhibit KRAS-G12C, then inhibition of KRAS-G12C is achieved, but these inhibitors cannot effectively target KRAS-G12D and KRAS-G12V mutants which lack reactive cysteines
Solution Approach 1:
The patent develops a single compound (Formula I) that can inhibit multiple KRAS mutant types (G12C, G12D, G12V) through a universal binding mechanism. The compound binds to the P-loop region which is conserved across different KRAS mutants, allowing one inhibitor to address multiple mutant variants that were previously required to be targeted by different approaches.
Solution Approach 2:
The invention changes the binding target parameter from the cysteine residue (specific to G12C) to the P-loop region (conserved across G12C, G12D, G12V). This parameter change in binding site selection enables the inhibitor to recognize and bind to multiple mutant types regardless of their specific amino acid substitutions at position 12.
2Reliability
If different approaches are developed for each KRAS mutant type, then each mutant can be specifically targeted, but the device complexity and number of compounds required increases
Solution Approach 1:
The patent employs a universal inhibitor design where a single compound (Formula I) performs the function of multiple mutant-specific inhibitors. By targeting the conserved P-loop region rather than mutant-specific residues, the compound achieves broad-spectrum inhibition across KRAS-G12C, KRAS-G12D, and KRAS-G12V, reducing the number of required compounds from multiple to one.
3Measurement precision
If KRAS-G12C specific inhibitors are used, then high selectivity for G12C is achieved, but the treatment scope is limited to cancers with G12C mutation only
Solution Approach 1:
The patent changes the selectivity parameter from targeting the unique cysteine residue of G12C to targeting the conserved P-loop region shared by G12C, G12D, and G12V mutants. This parameter change maintains selectivity for mutant KRAS proteins while expanding treatment applicability to cancers harboring any of these three common KRAS mutations.
Solution Approach 2:
The compound achieves multi-functionality by simultaneously providing mutant selectivity (distinguishing mutant KRAS from wild-type) and broad mutant coverage (inhibiting G12C, G12D, and G12V). This dual capability expands the treatment scope from G12C-specific cancers to include colorectal, pancreatic, and lung cancers with various KRAS mutations.
Data Source
AI summary
Compounds of Formula (I) or their pharmaceutically acceptable salts can inhibit the G12C, G12D and/or G12V mutants of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.